Le@P Technology, Inc. Appoints Dr. Donald J. Ciappenelli as Chief Executive Officer and Chairman

  
    
  
  
    
      Le@P Technology, Inc. (OTCBB:LPTC) today announced the appointment of 
      Dr. Donald J. Ciappenelli as Chairman of the Board of Directors and 
      Chief Executive Officer, effective November 1, 2006.
    
    
      Le@P’s Board of Directors are very pleased to 
      welcome Dr. Ciappenelli. The Board feels that with his broad life 
      sciences and new venture expertise, Dr. Ciappenelli will significantly 
      strengthen Le@P’s capabilities as he builds a 
      new team and product portfolio with his broad expertise in life sciences 
      and new ventures.
    
    
      Dr. Ciappenelli’s career spans over 25 years 
      of experience in the life sciences including research and development, 
      product commercialization and executive management at a number of 
      successful biotech ventures in the Cambridge, Massachusetts area. During 
      his career, he has founded and served on the executive management team 
      and the Board of Directors of 10 companies, three of which have reached 
      the public markets. He has specialized in the early stage development of 
      more than 50 life sciences startups, working with founding investors, 
      venture capitalists, executive management and leading scientists. He is 
      a former Director of the Chemical Laboratories and faculty member of the 
      Department of Chemistry at Harvard University. Dr. Ciappenelli has 
      particular expertise in the molecular sciences. His commercialization 
      experience includes successfully identifying, acquiring, and developing 
      core technologies from leading universities and successfully 
      transferring these assets into corporations and leveraging their 
      commercial potential.
    
    
      “I am excited about the opportunity to build 
      Le@P and look forward to developing a sustainable, successful business 
      by harnessing promising technologies and bringing new products to market,” 
      said Dr. Ciappenelli.
    
    
      Statements about Le@P’s future expectations, 
      including without limitation, future revenues and earnings, plans and 
      objectives for future operations, future agreements, future economic 
      performance, operations and all other statements in this press release 
      other than historical facts are “forward-looking 
      statements” within the meaning of Section 27A 
      of the Securities Act of 1933, Section 21E of the Securities Exchange 
      Act of 1934, and as that term is defined in the Private Securities 
      Litigation Reform Act of 1995. Le@P intends that such forward-looking 
      statements be subject to the safe harbor created thereby. Since these 
      statements involve risks and uncertainties, including but not limited to 
      economic, competitive, governmental, regulatory, contractual and 
      technological factors affecting Le@P’s 
      operations, markets and profitability, Le@P’s 
      actual performance could differ materially and adversely from its 
      projected results.
    
  
Le@P Technology, Inc. (OTCBB:LPTC) today announced the appointment
of Dr. Donald J. Ciappenelli as Chairman of the Board of Directors and
Chief Executive Officer, effective November 1, 2006.

   Le@P's Board of Directors are very pleased to welcome Dr.
Ciappenelli. The Board feels that with his broad life sciences and new
venture expertise, Dr. Ciappenelli will significantly strengthen
Le@P's capabilities as he builds a new team and product portfolio with
his broad expertise in life sciences and new ventures.

   Dr. Ciappenelli's career spans over 25 years of experience in the
life sciences including research and development, product
commercialization and executive management at a number of successful
biotech ventures in the Cambridge, Massachusetts area. During his
career, he has founded and served on the executive management team and
the Board of Directors of 10 companies, three of which have reached
the public markets. He has specialized in the early stage development
of more than 50 life sciences startups, working with founding
investors, venture capitalists, executive management and leading
scientists. He is a former Director of the Chemical Laboratories and
faculty member of the Department of Chemistry at Harvard University.
Dr. Ciappenelli has particular expertise in the molecular sciences.
His commercialization experience includes successfully identifying,
acquiring, and developing core technologies from leading universities
and successfully transferring these assets into corporations and
leveraging their commercial potential.

   "I am excited about the opportunity to build Le@P and look forward
to developing a sustainable, successful business by harnessing
promising technologies and bringing new products to market," said Dr.
Ciappenelli.

   Statements about Le@P's future expectations, including without
limitation, future revenues and earnings, plans and objectives for
future operations, future agreements, future economic performance,
operations and all other statements in this press release other than
historical facts are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934, and as that term is defined in the
Private Securities Litigation Reform Act of 1995. Le@P intends that
such forward-looking statements be subject to the safe harbor created
thereby. Since these statements involve risks and uncertainties,
including but not limited to economic, competitive, governmental,
regulatory, contractual and technological factors affecting Le@P's
operations, markets and profitability, Le@P's actual performance could
differ materially and adversely from its projected results.